A Phase 3, Multinational, Randomized, Open-label, Parallel-arm Study Of Avelumab (msb0010718c) In Combination With Axitinib (Inlyta(Registered)) Versus Sunitinib (Sutent(Registered)) Monotherapy In The First-line Treatment Of Patients With Advanced Renal Cell Carcinoma

Trial Profile

A Phase 3, Multinational, Randomized, Open-label, Parallel-arm Study Of Avelumab (msb0010718c) In Combination With Axitinib (Inlyta(Registered)) Versus Sunitinib (Sutent(Registered)) Monotherapy In The First-line Treatment Of Patients With Advanced Renal Cell Carcinoma

Recruiting
Phase of Trial: Phase III

Latest Information Update: 03 Oct 2017

At a glance

  • Drugs Avelumab (Primary) ; Axitinib; Sunitinib
  • Indications Renal cell carcinoma
  • Focus Registrational; Therapeutic Use
  • Acronyms JAVELIN Renal 101
  • Sponsors Pfizer
  • Most Recent Events

    • 19 Sep 2017 Planned End Date changed from 1 Sep 2020 to 30 Apr 2021.
    • 19 Sep 2017 Planned primary completion date changed from 28 Jun 2018 to 1 Dec 2018.
    • 06 Sep 2017 This trial was suspended in Germany, according to European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top